<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013154</url>
  </required_header>
  <id_info>
    <org_study_id>DEK-Dkk1-P102</org_study_id>
    <secondary_id>DKN-01</secondary_id>
    <secondary_id>LY2812176</secondary_id>
    <nct_id>NCT02013154</nct_id>
  </id_info>
  <brief_title>A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab</brief_title>
  <acronym>P102</acronym>
  <official_title>A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leap Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leap Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and tolerability of DKN-01 in combination with weekly
      paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric
      Malignancies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A is a Dose-Escalation Study in Participants with Relapsed or Refractory Esophageal
      Cancer or Gastro-Esophageal Junction Tumors. Parts B, C, D and E are expansion cohorts of
      Patients with Relapsed or Refractory Esophageal Cancer, Gastro-Esophageal Junction Tumors and
      Gastric Adenocarcinoma.

      Part F is a Dose-Escalation and Expansion Cohorts with DKN-01 + Pembrolizumab in Patients
      with Recurrent or Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer or Gastric
      Adenocarcinoma with Wnt Signaling Alterations.

      Patients who are unable to receive paclitaxel or pembrolizumab for any reason will be allowed
      to receive single agent DKN-01 as part of a monotherapy substudy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with dose limiting toxicities in Study Parts A and F which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03</measure>
    <time_frame>Baseline to End of cycle 1 (Part A cycle is 28 days and Part F cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse drug reactions and toxicities as evaluated by NCI CTCAE v4.03 of DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab</measure>
    <time_frame>Baseline until 30 days after last dose of study drug as assessed at a minimum of every 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response to treatment</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Disease Control Rate (ODCR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR (DoCR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Gastroesophageal Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Part A: DKN-01 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: DKN-01 (Dose Confirmation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01 Monotherapy Substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F DKN-01 (Dose Escalation+Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKN-01</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>Part A: DKN-01 (Dose Escalation)</arm_group_label>
    <arm_group_label>Part B: DKN-01 (Dose Confirmation)</arm_group_label>
    <arm_group_label>Part C: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part D: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>DKN-01 Monotherapy Substudy</arm_group_label>
    <arm_group_label>Part E: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part F DKN-01 (Dose Escalation+Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>Part A: DKN-01 (Dose Escalation)</arm_group_label>
    <arm_group_label>Part B: DKN-01 (Dose Confirmation)</arm_group_label>
    <arm_group_label>Part C: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part D: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part E: DKN-01 (Cohort Expansion)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>Part F DKN-01 (Dose Escalation+Expansion)</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In advanced esophagogastric malignancies:

          -  Participants with histologically confirmed recurrent or metastatic esophageal or
             gastro-esophageal junction squamous cell or adenocarcinoma or gastric adenocarcinoma
             with Wnt Signaling Alterations

          -  Participants must be refractory or intolerant to at least one prior therapy(ies) for
             metastatic or locally advanced disease

               -  If prior therapy consisted of palliative chemoradiation therapy, it will be
                  considered one line of therapy

               -  Prior treatment with paclitaxel as part of a definitive therapy regimen is
                  acceptable. Patients who are unable to receive paclitaxel for any reason will be
                  allowed to receive DKN-01 as a single agent.

               -  Prior treatment anti- programmed death-1 (PD-1)/ anti-PD-ligand 1 (PD-L1)
                  monoclonal antibody (mAb) is permitted in patients provided the patient's disease
                  is primary refractory, and the patient is not intolerant of pembrolizumab.
                  Patients who are not eligible to receive pembrolizumab will be allowed to receive
                  single agent DKN-01

          -  Tumor tissue for mandatory evaluation

          -  Must have one or more tumors measurable on radiographic imaging as defined by the
             Response Evaluation Criteria in Solid Tumors (RECIST). Patients with evaluable but not
             measurable disease per RECIST criteria may be enrolled with the approval of the
             medical monitor.

          -  Must be ≥18 years of age

          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. A
             performance status of 2 on the ECOG scale may be entered upon the review and approval
             of the medical monitor

          -  Disease-free of active second/secondary or prior malignancies for equal to or over 2
             years with the exception of currently treated basal cell, squamous cell carcinoma of
             the skin, or carcinoma &quot;in-situ&quot; of the cervix or breast

          -  Acceptable liver, renal, hematologic and coagulation function

          -  For men and women of child-producing potential, the use of effective contraceptive
             methods during the study and for 6 months following the last dose of study drug

        Exclusion Criteria:

          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction
             within the past 6 months, unstable arrhythmia

          -  Fridericia-corrected QT interval (QTcF) &gt; 470 msec (female) or &gt; 450 (male), or
             history of congenital long QT syndrome.

          -  Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study
             entry requiring systemic therapy

          -  Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface
             antigen (HBSAg), or hepatitis C antibodies (HCAb) unless HCV RNA is
             undetected/negative.

          -  Serious nonmalignant disease

          -  Pregnant or nursing women

          -  History of osteonecrosis of the hip or have evidence of structural bone abnormalities
             in the proximal femur on MRI scan that are symptomatic and clinically significant.

          -  Systemic central nervous system (CNS) malignancy or metastasis.

          -  Clinically significant peripheral neuropathy at the time of study entry. Patients with
             pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01

          -  Known osteoblastic bony metastasis

          -  History of known or suspected autoimmune disease with the specific exceptions of
             vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.

          -  Clinically-significant gastrointestinal disorders, such as perforation,
             gastrointestinal bleeding, or diverticulitis.

          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement
             therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of
             systemic treatment.

          -  Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days
             for nitrosoureas or mitomycin C)

          -  Treatment with low dose chemotherapy concurrent with radiation within 14 days prior to
             study entry

          -  Treatment with radiation therapy within 14 days prior to study entry

          -  Treatment with any other investigational agent within 30 days prior to study entry

          -  Previously treated with an anti-DKK-1 therapy

          -  Participants who have a history of hypersensitivity reactions to TAXOL® or other drugs
             formulated in Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these
             hypersensitivities will be eligible to receive single agent DKN-01.

          -  Significant allergy to a pharmaceutical therapy that, in the opinion of the
             investigator, poses an increased risk to the participant

          -  Treatment with corticosteroids (≥ 10 mg per day prednisone or equivalent) or other
             immune suppressive drugs within the 14 days prior to study entry

          -  Active substance abuse

          -  Receipt of any live vaccines within 30 days before the first dose of study treatment
             and while participating in the study

          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis

          -  History of interstitial lung disease

          -  Intolerance or severe hypersensitivity (≥Grade 3) to pembrolizumab and/or of its
             excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyndi Sirard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Leap Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyndi Sirard</last_name>
    <email>csirard@leaptx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Care Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Mata</last_name>
      <phone>310-231-2115</phone>
      <email>tmata@theangelesclinic.org</email>
    </contact>
    <contact_backup>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>smukarram@theangelesclinic.org</email>
    </contact_backup>
    <investigator>
      <last_name>Samuel Klempner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale - New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Dooley</last_name>
      <phone>203-785-2836</phone>
      <email>kirsten.dooley@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Stacey Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Staples</last_name>
      <phone>312-695-0703</phone>
      <email>rita.staples@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Victoria Villaflor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GI Research Line</last_name>
      <phone>617-632-5960</phone>
    </contact>
    <contact_backup>
      <last_name>Samantha Schuetz</last_name>
      <phone>617-632-5575</phone>
      <email>SamanthaR_Schuetz@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Enzinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Afflitto</last_name>
      <phone>617-724-1990</phone>
      <email>aafflitto@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Janet Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leighanne Hartman</last_name>
      <phone>919-668-1861</phone>
      <email>leighanne.hartman@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John Strickler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <contact_backup>
      <last_name>Erica Gentile</last_name>
      <phone>216-286-2292</phone>
      <email>erica.gentile@uhhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Eads, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Centre</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davendra Sohal, MD</last_name>
      <phone>216-444-8258</phone>
      <email>sohald@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Fields</last_name>
      <phone>(216) 442-5281</phone>
      <email>fieldsl@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Davendra Sohal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology / Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Glover</last_name>
      <phone>615-329-7469</phone>
      <email>nicole.glover@scresearch.net</email>
    </contact>
    <contact_backup>
      <last_name>Elias King</last_name>
      <phone>615-329-7645</phone>
      <email>Steven.King2@SarahCannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University / VICC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Phone Number</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <contact_backup>
      <last_name>Vicky Stephens</last_name>
      <phone>615-936-5869</phone>
      <email>vicki.stephens@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Goff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noureen Karimi</last_name>
      <phone>214-658-1985</phone>
      <email>NKarimi@MaryCrowley.Org</email>
    </contact>
    <investigator>
      <last_name>James Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CTRC @ The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <email>ctrcreferral@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Moseley</last_name>
      <phone>210-450-1799</phone>
      <email>moseleyj@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Tenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

